Opus Genetics Operating Income Over Time
| IRD Stock | 3.81 0.08 2.06% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Opus Genetics Performance and Opus Genetics Correlation. Will Pharmaceuticals sector continue expanding? Could Opus diversify its offerings? Factors like these will boost the valuation of Opus Genetics. Market participants price Opus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Opus Genetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
Understanding Opus Genetics requires distinguishing between market price and book value, where the latter reflects Opus's accounting equity. The concept of intrinsic value - what Opus Genetics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Opus Genetics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Opus Genetics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Opus Genetics and related stocks such as Acumen Pharmaceuticals, Seer Inc, and Agenus Inc Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABOS | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.9 M) | (19.6 M) | (45.2 M) | (61.1 M) | (114 M) | (102.6 M) | (97.5 M) |
| SEER | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (16.9 M) | (33.6 M) | (71.7 M) | (98 M) | (104.9 M) | (100.1 M) | (90.1 M) | (94.6 M) |
| AGEN | (18.8 M) | (19.1 M) | (6.7 M) | (25 M) | (43.3 M) | (80.7 M) | (107.5 M) | (103.8 M) | (123.8 M) | (70.1 M) | (117.2 M) | 25.7 M | (179.4 M) | (159.5 M) | (120.5 M) | (108.4 M) | (103 M) |
| INO | (6.9 M) | (21.6 M) | (23.5 M) | (19.5 M) | (39.5 M) | (34.3 M) | (76.2 M) | (83.6 M) | (94.1 M) | (111.1 M) | (124.1 M) | (301.2 M) | (267.6 M) | (143.9 M) | (112.4 M) | (101.2 M) | (96.1 M) |
| VTGN | (4.8 K) | (9 M) | (6.8 M) | (5 M) | (6.8 M) | (17.9 M) | (10.2 M) | (14.2 M) | (24.6 M) | (20 M) | (17.9 M) | (47.8 M) | (59.3 M) | (33 M) | (56 M) | (50.4 M) | (47.9 M) |
| HURA | (5.6 K) | (18.9 K) | (6.3 M) | (6.3 M) | (4.7 M) | (6.2 M) | (8.3 M) | (11.2 M) | (8.4 M) | (8.1 M) | (21.6 M) | (7.3 M) | (9.9 M) | (29.8 M) | (17.6 M) | (15.9 M) | (15.1 M) |
| ALEC | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (32.7 M) | (57.3 M) | (114.4 M) | (195.2 M) | (37.4 M) | (137.8 M) | (151.7 M) | (145 M) | (130.5 M) | (137 M) |
| CGTX | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.4 M) | (28.6 M) | (43.6 M) | (50.7 M) | (54 M) | (48.6 M) | (51 M) |
| TIL | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (33.6 M) | (155.6 M) | (206.2 M) | (159.2 M) | (73.5 M) | (66.2 M) | (69.5 M) |
| MCRB | (3 M) | (3 M) | (3 M) | (6.1 M) | (15.1 M) | (54.9 M) | (92.8 M) | (91.4 M) | (100.3 M) | (71.9 M) | (88.1 M) | (64.5 M) | (179.9 M) | (195.1 M) | (121.3 M) | (109.2 M) | (114.6 M) |
Opus Genetics and related stocks such as Acumen Pharmaceuticals, Seer Inc, and Agenus Inc Operating Income description
Operating Income is the amount of profit realized from Opus Genetics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Opus Genetics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Opus Genetics | IRD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 8 Davis Drive, |
| Exchange | NASDAQ Exchange |
null 3.81
Check out Opus Genetics Performance and Opus Genetics Correlation. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Opus Genetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.